Edition:
United States

Profile: Accelerate Diagnostics Inc (AXDX.O)

AXDX.O on Consolidated Issue listed on NASDAQ Capital Market

26.36USD
29 Sep 2016
Change (% chg)

$-0.78 (-2.87%)
Prev Close
$27.14
Open
$26.97
Day's High
$27.20
Day's Low
$25.91
Volume
309,062
Avg. Vol
326,318
52-wk High
$28.50
52-wk Low
$10.29

Accelerate Diagnostics, Inc., incorporated on December 24, 2012, is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company's technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types. The Company is focused on the development of a rapid diagnostic platform, the Accelerate ID/AST System (ID/AST System or Accelerate ID/AST System), intended for the diagnosis of infectious pathogens.

The ID/AST System utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. The Accelerate ID/AST System is the Company's in vitro diagnostic system and is intended for the identification and antibiotic susceptibility testing of pathogens associated with serious infections, including Gram-positive and Gram-negative organisms, such as Staphylococcus organisms, as well as yeasts. The ID/AST blood culture assay kit, which it refers to as the Blood Culture Assay Kit, is being investigated for its ability to provide ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Blood Culture Assay Kit consists of a panel of over 150 individual assays, which have the potential to support clinicians in prescribing optimal antibiotic therapy for patients in this critical condition. The ID/AST System features walk-away automation and consists of a fixed instrument and single-use test kit.

The Company competes with Becton, Dickinson and Company, bioMerieux, Danaher Corporation, Bruker Corporation, Nanosphere, T2 Biosystems, Abbott and Thermo Fisher Scientific.

Company Address

Accelerate Diagnostics Inc

3950 S. Country Club Road #470
Building 3-307
TUCSON   AZ   85714-2240
P: +1303.8638088
F: +1302.6555049

Company Web Links